Announcements Trials
Browse Landscape

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Observational 2

Sponsor

Cancer Type

Lymphoid 1

Conditions

Psoriasis 2Lymphoma, Follicular 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × deucravacitinib × Clear all
NCT07256015 2025-12-01

Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy

Bristol-Myers Squibb

Recruiting
200 enrolled
Lymphoid

Lymphoma, Follicular, Psoriasis

NCT06952465 2025-05-01

A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis

Bristol-Myers Squibb

Active not recruiting
2,000 enrolled

Psoriasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡